SA109300394B1 - ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها - Google Patents

ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها Download PDF

Info

Publication number
SA109300394B1
SA109300394B1 SA109300394A SA109300394A SA109300394B1 SA 109300394 B1 SA109300394 B1 SA 109300394B1 SA 109300394 A SA109300394 A SA 109300394A SA 109300394 A SA109300394 A SA 109300394A SA 109300394 B1 SA109300394 B1 SA 109300394B1
Authority
SA
Saudi Arabia
Prior art keywords
compound
isoquinolin
thiazolo
hydroxy
atoms
Prior art date
Application number
SA109300394A
Other languages
Arabic (ar)
English (en)
Inventor
روبرتو بيليكشياري
فلافيو موروني
Original Assignee
ويث
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ويث filed Critical ويث
Publication of SA109300394B1 publication Critical patent/SA109300394B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SA109300394A 2008-06-19 2009-06-17 ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها SA109300394B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7385708P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
SA109300394B1 true SA109300394B1 (ar) 2013-01-22

Family

ID=41087350

Family Applications (1)

Application Number Title Priority Date Filing Date
SA109300394A SA109300394B1 (ar) 2008-06-19 2009-06-17 ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها

Country Status (12)

Country Link
US (3) US8299090B2 (https=)
EP (2) EP2896626A1 (https=)
JP (2) JP5564495B2 (https=)
AR (1) AR072265A1 (https=)
AU (1) AU2009260060B2 (https=)
CA (1) CA2728454C (https=)
DK (1) DK2303895T3 (https=)
ES (1) ES2530815T3 (https=)
HK (1) HK1212698A1 (https=)
SA (1) SA109300394B1 (https=)
TW (1) TWI471329B (https=)
WO (1) WO2009155402A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728466A1 (en) 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
EP2729007A1 (de) 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20260030809A (ko) 2023-06-21 2026-03-06 테트라곤 바이오사이언시스 엘티디 Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005745B1 (en) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
US7696255B2 (en) 2005-08-01 2010-04-13 Wietek Holding Gmbh Process for the recycling of plastics
ES2559679T3 (es) 2006-06-20 2016-02-15 Abbvie Inc. Pirazoloquinazolinonas como inhibidores de PARP
CA2728466A1 (en) * 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها

Also Published As

Publication number Publication date
AU2009260060A1 (en) 2009-12-23
DK2303895T3 (en) 2015-01-12
TW201002725A (en) 2010-01-16
JP5564495B2 (ja) 2014-07-30
EP2896626A1 (en) 2015-07-22
CA2728454A1 (en) 2009-12-23
CA2728454C (en) 2017-01-17
WO2009155402A1 (en) 2009-12-23
TWI471329B (zh) 2015-02-01
AR072265A1 (es) 2010-08-18
US20150133443A1 (en) 2015-05-14
US8299090B2 (en) 2012-10-30
EP2303895B1 (en) 2014-09-24
US20130059843A1 (en) 2013-03-07
US8906935B2 (en) 2014-12-09
AU2009260060B2 (en) 2015-01-22
US20090318442A1 (en) 2009-12-24
JP2014122242A (ja) 2014-07-03
HK1212698A1 (en) 2016-06-17
US9265769B2 (en) 2016-02-23
JP2011525185A (ja) 2011-09-15
HK1156310A1 (en) 2012-06-08
EP2303895A1 (en) 2011-04-06
ES2530815T3 (es) 2015-03-05

Similar Documents

Publication Publication Date Title
SA109300394B1 (ar) ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
US20210188808A1 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
US10654867B2 (en) Heteroaryl estrogen receptor modulators and uses thereof
JP2023522045A (ja) アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用
EP1845970B1 (en) Tumor necrosis factor inhibitors
JP2013530951A (ja) ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物
EP4149629B1 (en) Purine derivatives as sik-3 inhibitors
KR20150021120A (ko) 헤테로아릴 화합물 및 이의 이용 방법
EP4112053A1 (en) Treatment of synucleinopathies
CN111718350B (zh) 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
HUE033124T2 (en) New anti-malarial drugs
SA109300406B1 (ar) ثينيل- وفيرانيل أيزوكوينولينونات وطرق لاستخدامها
EP3049400A1 (en) New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof
KR20200085815A (ko) 과증식성 질병의 치료를 위한 카페인산 유도체
TWI920088B (zh) Ｓｉｋ-３抑制劑及其用途
CN120424018A (zh) 5-氨基-1-取代-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用
WO2019046534A1 (en) INDOLOQUINOLINE COMPOUNDS DEUTTERED
HK1156310B (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them